Bradford A. Perez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bradford A. Perez has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Andreas N. Saltos
Moffitt Cancer Center, Tampa, FL
31 shared publications - Amer A. Beg
Moffitt Cancer Center 1 Department of Immunology Tampa, Florida
29 shared publications - Brian Ruffell
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
29 shared publications - Dana Foresman
Moffitt Cancer Center 1 Department of Immunology Tampa, Florida
29 shared publications - Hong Zheng
Moffitt Cancer Center 1 Department of Immunology Tampa, Florida
29 shared publications - Joseph O. Johnson
Analytic Microscopy Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
29 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8+ T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40 + IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40 + IFNβ in phase I clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in non–small cell lung cancer (NSCLC) patients. This approach to simultaneously target two major DC-activating pathways has the potential to significantly affect the solid tumor immunotherapy landscape.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8+ T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40 + IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40 + IFNβ in phase I clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in non–small cell lung cancer (NSCLC) patients. This approach to simultaneously target two major DC-activating pathways has the potential to significantly affect the solid tumor immunotherapy landscape.
- Open Access
- 8 April 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (4) , e011066
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
Background: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) is now a Food and Drug Administration (FDA)-approved treatment for melanoma. While this is a major milestone, there is room for improvement to increase clinical response rates and to further optimize the manufacturing of TIL products. In this study, we characterized the association of tumor-infiltrating B-cells (TIL-B) and tertiary lymphoid structures (TLSs) with clinical response to TIL therapy and tested whether the presence of B-cells in the tumor can be leveraged to optimize TIL manufacture. Methods: Tumor sections from TIL responders (R, n=9) and non-responders (NR, n=11) were analyzed by RNA sequencing, and immune cell content was estimated in silico. To study the association between B-cells and TIL expansion, we quantified B-cell subsets and TIL phenotype by flow cytometry. CD40L-induced effects on melanoma-infiltrating B-cells were analyzed by flow cytometry and scRNA-sequencing. Results: Tumors from TIL clinical responders had greater abundance of class-switched B-cells (p=0.007) and a greater TLS score (p=0.03) than those of NRs. In addition, greater abundance of B-cells (p≤0.05) and switched memory B-cells (CD27 + IgD−, p≤0.05) in the tumors were associated with greater TIL expansion. Stimulation of TIL-B through addition of CD40L during TIL ex vivo culture improved their expansion success rate from 33% to 67% (p=0.03). Similarly, the addition of CD40L to non-small cell lung cancer (NSCLC) TIL cultures shortened the manufacturing period by 1 week. Moreover, CD40L-enhanced TIL showed more stem-like T-cells (CD39 − CD69 − , p≤0.05) and an enrichment of neoantigen-reactive T-cell clones in NSCLC TIL. Gene expression analysis showed that CD40L induced gene expression changes in TIL-B after 48 hours in culture (126 differentially expressed genes (DEGs)), with minimal to no changes observed in other immune cell types (including 12 DEG in macrophages, 10 DEG in dendritic cells, and none in monocytes). B-cell DEGs included upregulated co-stimulatory ligands (CD83, CD58), chemokines (CCL22, CCL17), among others. CD40L-induced upregulation of CD58 by melanoma infiltrating B-cells was associated with successful TIL expansion. Conclusions: Our results show that CD40L-stimulated B-cells can be leveraged to enhance the quality and quantity of TIL. Clinical trial NCT05681780 is currently testing this concept applied to NSCLC TIL.
- 8 April 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (4) , e011066
Open AccessCD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion
Background: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) is now a Food and Drug Administration (FDA)-approved treatment for melanoma. While this is a major milestone, there is room for improvement to increase clinical response rates and to further optimize the manufacturing of TIL products. In this study, we characterized the association of tumor-infiltrating B-cells (TIL-B) and tertiary lymphoid structures (TLSs) with clinical response to TIL therapy and tested whether the presence of B-cells in the tumor can be leveraged to optimize TIL manufacture. Methods: Tumor sections from TIL responders (R, n=9) and non-responders (NR, n=11) were analyzed by RNA sequencing, and immune cell content was estimated in silico. To study the association between B-cells and TIL expansion, we quantified B-cell subsets and TIL phenotype by flow cytometry. CD40L-induced effects on melanoma-infiltrating B-cells were analyzed by flow cytometry and scRNA-sequencing. Results: Tumors from TIL clinical responders had greater abundance of class-switched B-cells (p=0.007) and a greater TLS score (p=0.03) than those of NRs. In addition, greater abundance of B-cells (p≤0.05) and switched memory B-cells (CD27 + IgD−, p≤0.05) in the tumors were associated with greater TIL expansion. Stimulation of TIL-B through addition of CD40L during TIL ex vivo culture improved their expansion success rate from 33% to 67% (p=0.03). Similarly, the addition of CD40L to non-small cell lung cancer (NSCLC) TIL cultures shortened the manufacturing period by 1 week. Moreover, CD40L-enhanced TIL showed more stem-like T-cells (CD39 − CD69 − , p≤0.05) and an enrichment of neoantigen-reactive T-cell clones in NSCLC TIL. Gene expression analysis showed that CD40L induced gene expression changes in TIL-B after 48 hours in culture (126 differentially expressed genes (DEGs)), with minimal to no changes observed in other immune cell types (including 12 DEG in macrophages, 10 DEG in dendritic cells, and none in monocytes). B-cell DEGs included upregulated co-stimulatory ligands (CD83, CD58), chemokines (CCL22, CCL17), among others. CD40L-induced upregulation of CD58 by melanoma infiltrating B-cells was associated with successful TIL expansion. Conclusions: Our results show that CD40L-stimulated B-cells can be leveraged to enhance the quality and quantity of TIL. Clinical trial NCT05681780 is currently testing this concept applied to NSCLC TIL.
- Open Access
- 29 August 2023
- Published by Elsevier in Practical Radiation Oncology
- Vol. 13 (5) , A4-A7
Table of Contents
- 29 August 2023
- Published by Elsevier in Practical Radiation Oncology
- Vol. 13 (5) , A4-A7
Open AccessTable of Contents
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S64-S65
Restrictive diets are not necessary with current bowel cleansing standards. Results of a non-inferiority clinical trial
Aims To evaluate the impact of restrictive diet within modern standards of preparation for colonoscopy. Methods We conducted a multicenter, randomized, parallel group, non-inferiority clinical trial. Population screening program FIT+ subjects were included. All followed a split-dose preparation with PEG+Asc 1L for morning colonoscopy. Bisacodyl was added in case of risk of inadequate preparation. Individuals were randomized to follow a 1-day low-residue diet (LRD) or free diet without restrictions (FD). A 5% non-inferiority margin was established. Bowel cleansing was assessed according to the Boston scale. In addition, diet and evacuating solution tolerability, perceived quality of the instructions and efficiency variables of colonoscopy were assessed ([Fig. 1]). Results 278 individuals assigned to FD and 275 to LRD were analyzed. Both groups were homogeneous with no significant differences between them. Risk of poor preparation was similar (FD 13.6% and 14.7% LRD, p=0.7). Adherence to PEG+Asc 1L was similar. There were no differences in terms of tolerability (67.8% vs. 67.9%) or in the instructions (95.7% vs. 96.7%). FD was better tolerated (94.7% vs. 83.2% p < 0.001). Adequate preparations rate were 96.4% vs. 97.8% (ẟ=1.4%, p=0.3). There were no differences in withdrawal times or in the adenoma detection rate. In the multivariate analysis, the diet had no influence on preparation quality. Conclusions It is not necessary to restrict the diet following the current standards of preparation for colonoscopy [1] [2] [3]. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S64-S65
Restrictive diets are not necessary with current bowel cleansing standards. Results of a non-inferiority clinical trial
Aims To evaluate the impact of restrictive diet within modern standards of preparation for colonoscopy. Methods We conducted a multicenter, randomized, parallel group, non-inferiority clinical trial. Population screening program FIT+ subjects were included. All followed a split-dose preparation with PEG+Asc 1L for morning colonoscopy. Bisacodyl was added in case of risk of inadequate preparation. Individuals were randomized to follow a 1-day low-residue diet (LRD) or free diet without restrictions (FD). A 5% non-inferiority margin was established. Bowel cleansing was assessed according to the Boston scale. In addition, diet and evacuating solution tolerability, perceived quality of the instructions and efficiency variables of colonoscopy were assessed ([Fig. 1]). Results 278 individuals assigned to FD and 275 to LRD were analyzed. Both groups were homogeneous with no significant differences between them. Risk of poor preparation was similar (FD 13.6% and 14.7% LRD, p=0.7). Adherence to PEG+Asc 1L was similar. There were no differences in terms of tolerability (67.8% vs. 67.9%) or in the instructions (95.7% vs. 96.7%). FD was better tolerated (94.7% vs. 83.2% p < 0.001). Adequate preparations rate were 96.4% vs. 97.8% (ẟ=1.4%, p=0.3). There were no differences in withdrawal times or in the adenoma detection rate. In the multivariate analysis, the diet had no influence on preparation quality. Conclusions It is not necessary to restrict the diet following the current standards of preparation for colonoscopy [1] [2] [3]. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany